The laboratory evaluates the safety and effectiveness of an investigational drug aimed at slowing the progression of Alzheimer's Disease. In Alzheimer's Disease, a protein called beta-amyloid gathers in the brain and is thought to cause symptoms like memory loss and confusion. It has been shown that anti beta-amyloid antibodies, administered intravenously, can reduce or stop the progression of Alzheimer's Disease.
This vaccine-based approach could be an effective therapy for people with mild or moderate Alzheimer's Disease. Medication currently available for Alzheimer's Disease generally attempts to alleviate the damage inflicted to brain cells. What is interesting about this vaccination study, is that it attempts to eliminate the protein causing the damage.
Iliana Papazova, study coordinator
Samir Niazi, study coordinator